Your Client Rank:
Loading...
99
Updated 15-Aug-2025
| Company | Sales | Gross M. | SGA % Sales | R&D % Sales | Trading M. | Tax Rate | Net Income | EPS |
| | | | | | | | |
| Ascendis | 50.4% | -0.6% | -24.4% | -29.5% | | | | |
| Lilly | 17.8% | 0.5% | -5.2% | -10.8% | 10.0% | -0.5% | 30.4% | 30.8% |
| Vertex | 10.8% | 0.7% | -1.0% | -19.0% | 50.2% | -26.1% | >100% | >100% |
| Daiichi | 9.3% | 1.4% | 2.4% | -3.8% | 5.3% | 3.3% | 12.9% | 14.0% |
| Novo | 7.9% | -0.2% | -0.5% | -2.5% | -0.7% | 0.9% | 7.4% | 8.9% |
| AbbVie | 6.7% | 0.0% | -3.5% | -6.3% | 4.2% | -2.2% | 12.7% | 12.6% |
| Sanofi | 5.7% | 0.7% | -2.3% | -1.9% | 4.9% | 0.4% | 9.1% | 10.0% |
| Astra | 5.7% | 0.1% | -1.5% | -1.0% | 3.6% | 0.8% | 10.1% | 10.3% |
| Chugai | 5.5% | 1.3% | -3.1% | -1.7% | 3.5% | -1.3% | 9.7% | 10.5% |
| Eisai | 5.4% | -0.4% | -2.7% | -4.2% | 12.7% | 2.4% | 15.6% | 15.9% |
| JNJ | 4.9% | -0.3% | -1.6% | -4.5% | 3.4% | 1.8% | 6.8% | 7.7% |
| Regeneron | 4.9% | 0.1% | -2.1% | 0.5% | 0.2% | 8.1% | 4.0% | 4.5% |
| Shionogi | 4.5% | -0.7% | -0.3% | -2.1% | -1.4% | 4.3% | 2.1% | 2.6% |
| Novartis | 4.5% | -0.3% | -0.7% | 0.1% | 0.4% | 0.6% | 5.9% | 7.5% |
| Gilead | 3.9% | -0.1% | -2.9% | -11.6% | 10.5% | -5.7% | 18.0% | 18.5% |
| Amgen | 3.4% | -0.1% | -1.3% | 3.0% | -0.7% | 0.9% | 4.2% | 4.2% |
| Roche | 3.3% | -0.1% | -1.9% | -0.5% | 1.5% | 3.1% | 5.0% | 5.1% |
| Teva | 3.1% | 1.4% | -5.9% | 0.4% | 3.7% | 3.7% | 9.4% | 8.0% |
| Merck | 2.4% | 0.1% | -1.3% | -4.7% | 2.3% | 0.4% | 5.2% | 5.8% |
| Glaxo | 1.9% | 0.0% | -0.1% | 0.2% | 1.0% | 0.3% | 3.5% | 3.4% |
| Takeda | 1.1% | 0.4% | -0.2% | 1.2% | 14.5% | -8.1% | 3.4% | 4.2% |
| Lundbeck | 1.1% | 0.2% | -0.8% | 4.3% | 5.3% | 9.2% | 0.9% | -2.9% |
| Bayer | 1.0% | 1.2% | -1.7% | -1.0% | 15.1% | | 2.5% | 2.1% |
| Biogen | -0.6% | 0.4% | 0.1% | 0.2% | 1.2% | 2.6% | 1.5% | 1.2% |
| Pfizer | -4.0% | 0.3% | 0.1% | 2.7% | -1.1% | 1.7% | -6.1% | -6.0% |
| Astellas | -4.3% | -0.9% | -4.5% | 2.2% | 2.7% | -6.9% | -2.8% | 0.5% |
| Bristol | -5.4% | 0.0% | 1.3% | -13.3% | 26.4% | -20.5% | 34.3% | 34.4% |
| Neurocrine | | | | | | | | |
| EU Major | 4.3% | 0.3% | -1.5% | -0.9% | 2.8% | 0.7% | 6.6% | 6.9% |
| Other EU | 12.3% | 0.4% | -8.0% | -5.9% | 47.3% | -23.4% | >100% | |
| US Major | 4.4% | 0.3% | -2.1% | -7.0% | 6.1% | -1.8% | 11.2% | 17.3% |
| US Big Biotech | 4.3% | 0.2% | -2.2% | -6.3% | 5.6% | -2.5% | 12.2% | 10.0% |
| Other US | 3.1% | 1.4% | -5.9% | 0.4% | 3.7% | 3.7% | 9.4% | 8.0% |
| Japanese | 2.9% | 0.5% | -0.7% | -0.6% | 6.6% | -1.3% | 5.9% | 7.6% |
